Program
Herpes Zoster Vaccine
Also written as “Herpes Zoster Vaccine, Live”, “Herpes Zoster vaccine (GSK 1437173A)” and “Herpes Zoster vaccine (GSK1437173A)”.
Its studies are mostly in Herpes Zoster, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 30 open or running | phase 3since Jan 10, 2013 | Jan 10, 2013 | none ahead |
| Changchun BCHT Biotechnology | 11 open or running | phase 4since Apr 23, 2025 | Apr 23, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 10, 2013First study: phase 3 study in Herpes ZosterNew to GlaxoSmithKlineGlaxoSmithKline · NCT01767467 · 568 enrolled · United States, Australia, Belgium and more
- Mar 28, 2013Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT01827839 · 96 enrolled · Canada, Russian Federation
- Feb 27, 2014Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT02075515 · 651 enrolled · United States, Belgium, Canada
- Apr 23, 2025Changchun BCHT Biotechnology’s first study: phase 4 study in Herpes ZosterNew to Changchun BCHT BiotechnologyChangchun BCHT Biotechnology · NCT06961721 · 600 planned
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06961721Herpes Zoster | 4 | Not yet recruiting | Changchun BCHT Biotechnology | Jul 2025 | 600 |
| NCT02075515Herpes Zoster · United States, Belgium, Canada | 3 | Completed | GlaxoSmithKline | Apr 29, 2015 | 651 |
| NCT01827839Herpes Zoster · Canada, Russian Federation | 3 | Completed | GlaxoSmithKline | Feb 10, 2014 | 96 |
| NCT01767467Herpes Zoster · United States, Australia, Belgium and more | 3 | Completed | GlaxoSmithKline | Jan 7, 2016 | 568 |
How it is read
Names in the registry
- “Herpes Zoster Vaccine, Live”, 1 entry
- “Herpes Zoster vaccine (GSK 1437173A)”, 1 entry
- “Herpes Zoster vaccine (GSK1437173A)”, 1 entry
- “Herpes zoster vaccine (GSK 1437173A)”, 1 entry
Conditions, from the studies’ own filings
- Herpes Zoster, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.